CADL · Candel Therapeutics, Inc.

The thesis

Candel Therapeutics' case still rests on one event: submission of its biologics license application (BLA) for aglatimagene besadenovec in localized prostate cancer, planned for the fourth quarter of 2026. The shares closed at $8.67 on 28 October 2026 (adjusted daily close), below the $8.91 close of 15 October 2026 and the $9.00 level the earlier note used as its line, so the price keeps contradicting a filing timetable that the company has not changed.

Jefferies initiated coverage with a Buy rating and a $25 price target on 22 October 2026, according to Benzinga. The shares were lower six days later. The submission, or the quarter ending on 31 December 2026 without one, settles the question, and the Q3 report expected around 12 November 2026 may restate the timetable first.

The narrative is maturing: the Phase 3 result has been public since 2 June 2026, and the B of A Securities upgrade of 21 September 2026 and the Jefferies initiation of 22 October 2026 have not lifted the price. The 14-day relative strength index (RSI), a momentum gauge where readings under 30 mark heavy selling, was 38.3 on 28 October 2026, against 16.5 on 15 October 2026.

Bullish and bearish views on Candel Therapeutics, Inc.

The bull case on Candel Therapeutics, Inc. (CADL), in brief: Filing timetable keeps being confirmed. The bear case: The shares sit well below their high.

Bull case

• Filing timetable keeps being confirmed. The 30 September 2026 ASTRO release says biodistribution and shedding data from the PrTK05 Phase 2 trial remain on track for the Q4 2026 BLA. The same plan appeared in the 13 August 2026 results release.
• The pivotal result is statistically positive. The Phase 3 trial (n=745) reported a disease-free survival hazard ratio of 0.70 (95% confidence interval 0.52-0.94, p=0.016), published in The Lancet Oncology on 2 June 2026.
• Sell-side coverage is widening. Jefferies initiated at Buy with a $25 target on 22 October 2026. B of A Securities upgraded to Buy with an $18 target on 21 September 2026, and H.C. Wainwright's Buy carries a $23 target (13 August 2026).
• Cash covers the filing and beyond. Cash and equivalents were $201.6M at 30 June 2026, and the company guides to a runway into Q1 2028 (13 August 2026 results release).
• Commercial groundwork exists. The company announced a commercialization agreement with EVERSANA on 29 April 2026 to support a potential U.S. launch after the planned BLA submission.

Bear case

• The shares sit well below their high. The close of $8.67 on 28 October 2026 is 36.9% below the $13.75 52-week high and 13.4% lower than three months earlier. The 28 August 2026 close was $13.07.

• The loan covenant ties price to liquidity. The Trinity term loan carries a market-capitalisation covenant near $550M. StockTitan put the market value near $977.9M at $12.78 on 5 September 2026, and the shares have since closed at $8.67.
• Losses are widening ahead of any revenue. Q2 2026 EPS was $(0.52) against a $(0.23) consensus. R&D was $19.8M versus $7.0M a year earlier, and the net loss was $38.9M versus $4.8M, including $12.2M of mostly warrant-related other expense (13 August 2026 release).
• Regulatory reception is uncertain. The upper end of the hazard-ratio interval is 0.94, and a legacy data-integrity matter tied to former leadership is a risk to BLA acceptance.

Price setup

The adjusted daily close was $8.67 on 28 October 2026, with a 52-week high of $13.75 (36.9% below) and a three-month price change of -13.4%. The close sits under both the $9.00 level and the $8.91 close of 15 October 2026. The next round level down is $8.00.

Crowding evidence is limited. No SEC filings or insider transactions appear for the period since the previous note, and no share issuance has been reported. An earnings date is approaching: a third-party estimate puts the Q3 report on 12 November 2026, before the market open, and the company has not confirmed it.

Selling pressure has eased from the extreme of 15 October 2026, but the shares have not recovered the $8.91 close of that date. Price has not rewarded the filing story since the 28 August 2026 close of $13.07.

Catalysts, next 30 days

• ~12 November 2026, est.: Q3 2026 financial results. The report updates cash against the runway guided into Q1 2028 and may restate the BLA timetable. Q2 was reported on 13 August 2026.
• 31 December 2026: end of the planned submission quarter. A submission announced by this date confirms the timetable. A quarter ending without one breaks the filing component of the case.
• ~2027-02, est.: FDA filing-acceptance decision. Acceptance follows roughly 60 days after a Q4 2026 submission and would be the first regulatory validation of the dataset.

Elapsed catalysts

• November 2026, dates not confirmed: investor conferences. The company announced on 27 October 2026 that it will present at November investor conferences. Management commentary on filing timing is the item to watch. (passed 10d ago)

What would change the view

The case breaks if the company discloses a delay of the prostate BLA beyond the fourth quarter of 2026, or if the quarter ends on 31 December 2026 with no submission announced. Disclosure of pressure on the Trinity market-capitalisation covenant would also break it, because the loan links price weakness to a cash pledge against the $50M facility.

On price, a daily close below $8.00 would extend the decline that has run since the $13.07 close of 28 August 2026 and bring the covenant risk closer.

The case strengthens if the Q3 report reaffirms the Q4 timetable and the shares close back above $9.00, or if a submission is announced.

What it trades with

Candel trades on its own regulatory timetable and shows no current link to a thematic cluster. Small-cap biotech sentiment sets the backdrop for financing risk. The $25 Jefferies target, the $23 H.C. Wainwright target and the $18 B of A Securities target all sit far above the $8.67 close, and the 2 October 2026 MarketBeat average target was $19.29 across 10 analysts. Warrant fair-value marks make reported EPS worsen when the shares rise, so quarterly earnings can move against the share price.